---
title: "Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Product comparison"
description: "Formulary evidence on Adrabetadex (Lembaz, VTS-270) in Infantile-onset Niemann-Pick disease type C: Product comparison. Topics: Approval basis and labeled population compared with the two other approved NPC treatments; Arimoclomol: U.S. indication; Arimoclomol: recommended oral dosage by actual body weight, in combination with miglustat; Arimoclomol: dosage in renal impairment; 23 further topics. 27 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description/product-comparison"
published: "2026-11-19T12:08:36-05:00"
modified: "2026-11-19T12:08:36-05:00"
---

# Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Product comparison

<a id="heading-2.1.2.14"></a>

## 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

### Approval basis and labeled population compared with the two other approved NPC treatments

> “Lembaz marks the FDA’s third approval for NPC after IntraBio’s Aqneursa and Zevra’s Miplyffa were approved in the same month in 2024.”
> “To Lembaz’s advantage, it’s the only treatment approved based on survival data.”
> “The other two treatments were cleared on data showing they improved disease progression and neurological function.”
> “Lembaz is also indicated for the smallest of patients starting at 15 pounds compared to 33 pounds with Aqneursa and two years of age with Miplyffa.”

Source: [Fierce Pharma LEMBAZ approval report (2026)](https://www.fiercepharma.com/pharma/beren-clinches-long-awaited-fda-nod-niemann-pick-disease)

<a id="topic-2.1.2.14-2"></a>

### Arimoclomol: U.S. indication

> “MIPLYFFA is indicated for use in combination with miglustat for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adult and pediatric patients 2 years of age and older.”
> “There were insufficient data to determine the effectiveness of the use of MIPLYFFA without miglustat for the treatment of neurological manifestations in patients with NPC.”

Source: [Miplyffa prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214927s000lbl.pdf)

<a id="topic-2.1.2.14-3"></a>

### Arimoclomol: recommended oral dosage by actual body weight, in combination with miglustat

| Actual body weight | Prescribing information |
| --- | --- |
| 8 kg to 15 kg | “8 kg to 15 kg, is 47 mg three times a day” |
| More than 15 kg to 30 kg | “15 kg to 30 kg, is 62 mg three times a day” |
| More than 30 kg to 55 kg | “30 kg to 55 kg, is 93 mg three times a day” |
| More than 55 kg | “55 kg, is 124 mg three times a day” |

Source: [Miplyffa prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214927s000lbl.pdf)

> “The recommended oral dosage of MIPLYFFA, in combination with miglustat, for patients with an actual body weight of:”
> “Administer MIPLYFFA with or without food.”
> “If a dose of MIPLYFFA is missed, advise the patient to skip the missed dose and to resume taking the prescribed dose at the next scheduled time.”

Source: [Miplyffa prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214927s000lbl.pdf)

<a id="topic-2.1.2.14-4"></a>

### Arimoclomol: dosage in renal impairment

> “The recommended dosage of MIPLYFFA, in combination with miglustat, in patients with an eGFR ≥ 50 mL/minute is the same as the recommended dosage in patients with normal renal function”
> “For patients with an eGFR ≥ 15 to < 50 mL/minute, the recommended oral dosage of MIPLYFFA, in combination with miglustat, for patients with an actual body weight of”
> “8 kg to 15 kg, is 47 mg two times a day”
> “55 kg, is 124 mg two times a day”
> “The pharmacokinetics of arimoclomol have not been evaluated in patients with eGFR < 15 mL/minute.”

Source: [Miplyffa prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214927s000lbl.pdf)

<a id="topic-2.1.2.14-5"></a>

### Arimoclomol: dosage forms, packaging, and national drug codes

> “Capsules: 47 mg, 62 mg, 93 mg and 124 mg of arimoclomol.”
> “MIPLYFFA (arimoclomol) capsules are supplied in high-density polyethylene (HDPE) bottles with child-resistant closure as follows:”

Source: [Miplyffa prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214927s000lbl.pdf)

| Strength | Package configuration | NDC |
| --- | --- | --- |
| 47 mg | “Bottle of 90 capsules” | “72542-147-01” |
| 62 mg | “Bottle of 90 capsules” | “72542-162-01” |
| 93 mg | “Bottle of 90 capsules” | “72542-193-01” |
| 124 mg | “Bottle of 90 capsules” | “72542-124-01” |

Source: [Miplyffa prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214927s000lbl.pdf)

<a id="topic-2.1.2.14-6"></a>

### Arimoclomol: oral and feeding tube administration

> “Swallow MIPLYFFA whole. However, for patients who have difficulty swallowing capsules, administer MIPLYFFA in one of two ways:”
> “Carefully open the capsule and sprinkle the entire contents into 15 mL of water or apple juice or 15 mL of soft food (e.g., applesauce, pudding, or yogurt).”
> “Carefully open the capsule and sprinkle the entire contents into 20 mL of water.”
> “Administer the entire mixture immediately via feeding tube.”
> “Flush the feeding tube with 5 mL of water after administration.”

Source: [Miplyffa prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214927s000lbl.pdf)

<a id="topic-2.1.2.14-7"></a>

### Arimoclomol: warnings and precautions

> “Hypersensitivity reactions such as urticaria and angioedema have been reported in patients treated with MIPLYFFA during Trial 1”
> “The reactions occurred within the first two months of treatment. Discontinue MIPLYFFA in patients who develop severe hypersensitivity reactions.”
> “Based on findings from animal reproduction studies, MIPLYFFA may cause embryofetal harm when administered during pregnancy.”
> “Across clinical trials of MIPLYFFA consisting of patients with NPC, healthy subjects, and patients with other diseases, there were mean increases in serum creatinine of 10% to 20% compared to baseline.”
> “During MIPLYFFA treatment, use alternative measures that are not based on creatinine to assess renal function such as BUN, cystatin C, or measured GFR.”

Source: [Miplyffa prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214927s000lbl.pdf)

<a id="topic-2.1.2.14-8"></a>

### Arimoclomol: adverse reactions in Trial 1

> “The safety of MIPLYFFA was evaluated in a randomized, double-blind, placebo-controlled, 12-month trial (Trial 1), which included 50 patients 2 to 19 years old with NPC”
> “Patients received weight-adjusted doses of MIPLYFFA (31 to 124 mg orally three times daily); 28 of the patients were exposed to MIPLYFFA for one year. In Trial 1, 78% of patients received miglustat.”
> “The most common adverse reactions in Trial 1 (≥ 15%) in MIPLYFFA-treated patients who also received miglustat were upper respiratory tract infection, diarrhea, and decreased weight.”
> “Three (6%) of the MIPLYFFA-treated patients had the following adverse reactions that led to withdrawal from Trial 1: increased serum creatinine (one patient), and progressive urticaria and angioedema (two patients).”
> “Serious adverse reactions reported in MIPLYFFA-treated patients in Trial 1 were hypersensitivity reactions including urticaria and angioedema.”

Source: [Miplyffa prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214927s000lbl.pdf)

<a id="topic-2.1.2.14-9"></a>

### Arimoclomol: adverse reactions in at least 8% of treated participants who also received miglustat in Trial 1

| Adverse reaction | MIPLYFFA with miglustat, N=26, n (%) | Placebo with miglustat, N=13, n (%) |
| --- | --- | --- |
| Upper respiratory tract infection | “8 (31)” | “2 (15)” |
| Diarrhea | “6 (23)” | “3 (23)” |
| Decreased weight | “4 (15)” | “0” |
| Lower respiratory tract infection | “3 (12)” | “1 (8)” |

Source: [Miplyffa prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214927s000lbl.pdf)

<a id="topic-2.1.2.14-10"></a>

### Arimoclomol: drug interaction with OCT2 substrates

> “Arimoclomol is an inhibitor of the organic cationic transporter 2 (OCT2) transporter and may increase the exposure of drugs that are OCT2 substrates”
> “When MIPLYFFA is used concomitantly with OCT2 substrates, monitor for adverse reactions and reduce the dosage of the OCT2 substrate.”

Source: [Miplyffa prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214927s000lbl.pdf)

<a id="topic-2.1.2.14-11"></a>

### Arimoclomol: pediatric and geriatric use

> “The safety and effectiveness of MIPLYFFA have not been established in pediatric patients younger than 2 years of age.”
> “NPC is largely a disease of pediatric and young adult patients. Clinical trials of MIPLYFFA in combination with miglustat in patients with NPC did not include patients aged 65 years or older.”

Source: [Miplyffa prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214927s000lbl.pdf)

<a id="topic-2.1.2.14-12"></a>

### Levacetylleucine: U.S. indication in Niemann-Pick disease type C

> “AQNEURSA® is indicated for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adults and pediatric patients weighing ≥15 kg.”

Source: [Aqneursa prescribing information (2026)](https://www.aqneursa.com/wp-content/prescribing-information.pdf)

<a id="topic-2.1.2.14-13"></a>

### Levacetylleucine: recommended dosage by body weight

| Body weight | Morning dose | Afternoon dose | Evening dose |
| --- | --- | --- | --- |
| 15 kg to less than 25 kg | “1 gram” | “No Dose” | “1 gram” |
| 25 kg to less than 35 kg | “1 gram” | “1 gram” | “1 gram” |
| 35 kg or more | “2 grams” | “1 gram” | “1 gram” |

Source: [Aqneursa prescribing information (2026)](https://www.aqneursa.com/wp-content/prescribing-information.pdf)

<a id="topic-2.1.2.14-14"></a>

### Levacetylleucine: basis of the dosage and packet strength

> “The recommended dosage of AQNEURSA to be administered orally, with or without food, is based on the patient’s actual body weight (kg), as shown in Table 1”
> “One AQNEURSA packet contains 1 gram levacetylleucine.”
> “For AQNEURSA doses of 2 grams, prepare two packets individually”
> “The approved dosage regimen is based on body weight and not age.”

Source: [Aqneursa prescribing information (2026)](https://www.aqneursa.com/wp-content/prescribing-information.pdf)

<a id="topic-2.1.2.14-15"></a>

### Levacetylleucine: granules for oral suspension, strength and appearance

> “For oral suspension: 1 gram levacetylleucine in a unit-dose packet.”
> “For oral suspension: 1 gram levacetylleucine as white to off-white strawberry flavored granules in a unit-dose packet.”

Source: [Aqneursa prescribing information (2026)](https://www.aqneursa.com/wp-content/prescribing-information.pdf)

<a id="topic-2.1.2.14-16"></a>

### Levacetylleucine: warning for embryo-fetal toxicity

> “Based on findings from animal reproduction studies, AQNEURSA may cause embryo-fetal harm when administered during pregnancy.”
> “Administration of levacetylleucine to pregnant rats and rabbits during the period of organogenesis caused an increase in embryo-fetal death (post implantation loss/resorption) and skeletal malformations at a dose that was approximately 1.4-fold and 6-fold, respectively, the maximum recommended human dose (MRHD) of 4 g/day of levacetylleucine (based on body surface area).”
> “The decision to continue or discontinue AQNEURSA treatment during pregnancy should consider the female’s need for AQNEURSA, the potential drug-related risks to the fetus, and the potential adverse outcomes from untreated maternal disease.”
> “For females of reproductive potential, verify that the patient is not pregnant prior to initiating treatment with AQNEURSA.”
> “Advise females of reproductive potential to use effective contraception during treatment with AQNEURSA and for 7 days after the last dose if AQNEURSA is discontinued”

Source: [Aqneursa prescribing information (2026)](https://www.aqneursa.com/wp-content/prescribing-information.pdf)

<a id="topic-2.1.2.14-17"></a>

### Levacetylleucine: adverse reactions in NPC, safety population and exposure in Trial 1

> “The safety of AQNEURSA was evaluated in Trial 1, which included a total of 60 patients with Niemann-Pick disease Type C (NPC), in a placebo-controlled, randomized, crossover trial”
> “The mean (SD) treatment duration of AQNEURSA was 86.2 (4.7) days (69 min, 97 max); the mean (SD) treatment duration on placebo was 87.3 (4.8) days (78 min, 113 max).”
> “In NPC, the most common adverse reactions (incidence ≥5% and greater than placebo) are abdominal pain, dysphagia, upper respiratory tract infections, and vomiting.”

Source: [Aqneursa prescribing information (2026)](https://www.aqneursa.com/wp-content/prescribing-information.pdf)

<a id="topic-2.1.2.14-18"></a>

### Levacetylleucine: adverse reactions in NPC at an incidence of 5% or more in Treatment Period I of Trial 1

| Adverse reaction | AQNEURSA, N=30, n (%) | Placebo, N=30, n (%) |
| --- | --- | --- |
| Upper respiratory tract infection | “5 (17)” | “1 (3)” |
| Abdominal pain | “2 (7)” | “0 (0)” |
| Dysphagia | “2 (7)” | “0 (0)” |
| Vomiting | “2 (7)” | “0 (0)” |

Source: [Aqneursa prescribing information (2026)](https://www.aqneursa.com/wp-content/prescribing-information.pdf)

<a id="topic-2.1.2.14-19"></a>

### Levacetylleucine: rosacea and thrombocytopenia in NPC Trial 1

> “One patient experienced an exacerbation of rosacea during Trial 1 that responded to treatment. AQNEURSA was not discontinued.”
> “Thrombocytopenia with platelets < 100 10^3 cells/µL was observed in four patients during Treatment Period 1 of Trial 1, all of whom were receiving miglustat for 42 days or longer at the time of enrollment.”
> “In two of these patients, the thrombocytopenia was present at baseline. In the other two patients, the thrombocytopenia developed during Trial 1.”

Source: [Aqneursa prescribing information (2026)](https://www.aqneursa.com/wp-content/prescribing-information.pdf)

<a id="topic-2.1.2.14-20"></a>

### Levacetylleucine: pediatric use in NPC and supporting pharmacokinetic data

> “The safety and effectiveness of AQNEURSA for the treatment of NPC have been established in 23 pediatric patients weighing ≥15 kg in Trial 1.”
> “Use of AQNEURSA for this indication is supported by evidence from one adequate and well-controlled study in adults and pediatric patients weighing ≥15 kg with additional pharmacokinetic data from 40 adults and 17 pediatric patients who participated in two open-label studies”

Source: [Aqneursa prescribing information (2026)](https://www.aqneursa.com/wp-content/prescribing-information.pdf)

<a id="topic-2.1.2.14-21"></a>

### Miglustat: U.S. labeled indication limited to type 1 Gaucher disease

> “ZAVESCA is indicated as monotherapy for the treatment of adult patients with mild to moderate type 1 Gaucher disease for whom enzyme replacement therapy is not a therapeutic option (e.g. due to allergy, hypersensitivity, or poor venous access).”
> “Capsules: 100 mg of miglustat, white opaque hard gelatin capsules with “OGT 918” printed in black on the cap and “100” printed in black on the body.”

Source: [ZAVESCA prescribing information (2020)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021348s016lbl.pdf)

<a id="topic-2.1.2.14-22"></a>

### Miglustat: European Union indication and dosage in Niemann-Pick type C disease

> “Zavesca is indicated for the treatment of progressive neurological manifestations in adult patients and paediatric patients with Niemann-Pick type C disease (see sections 4.4, and 5.1).”
> “Therapy should be directed by physicians who are knowledgeable in the management of Gaucher disease or Niemann-Pick type C disease, as appropriate.”
> “The recommended dose for the treatment of adult patients with Niemann-Pick type C disease is 200 mg three times a day.”
> “The recommended dose for the treatment of adolescent patients (12 years of age and above) with Niemann-Pick type C disease is 200 mg three times a day.”
> “Dosing in patients under the age of 12 years should be adjusted on the basis of body surface area as illustrated below:”
> “There is limited experience with the use of Zavesca in Niemann-Pick type C disease patients under the age of 4 years.”
> “Zavesca can be taken with or without food.”

Source: [European Medicines Agency Zavesca product information (2026)](https://www.ema.europa.eu/en/documents/product-information/zavesca-epar-product-information_en.pdf)

<a id="topic-2.1.2.14-23"></a>

### Miglustat: European Union dose by body surface area in Niemann-Pick type C disease, patients under 12 years

| Body surface area (m2) | Recommended dose |
| --- | --- |
| More than 1.25 | “200 mg three times a day” |
| More than 0.88 to 1.25 | “200 mg twice a day” |
| More than 0.73 to 0.88 | “100 mg three times a day” |
| More than 0.47 to 0.73 | “100 mg twice a day” |
| 0.47 or less | “100 mg once a day” |

Source: [European Medicines Agency Zavesca product information (2026)](https://www.ema.europa.eu/en/documents/product-information/zavesca-epar-product-information_en.pdf)

<a id="topic-2.1.2.14-24"></a>

### Miglustat: European Union dose in renal impairment

> “Pharmacokinetic data indicate increased systemic exposure to miglustat in patients with renal impairment.”
> “Use in patients with severe renal impairment (creatinine clearance < 30 mL/min/1.73 m2) is not recommended (see sections 4.4 and 5.2).”

Source: [European Medicines Agency Zavesca product information (2026)](https://www.ema.europa.eu/en/documents/product-information/zavesca-epar-product-information_en.pdf)

<a id="topic-2.1.2.14-25"></a>

### Miglustat: European Union contraindications, warnings, and precautions

> “Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.”
> “Approximately 37% of patients in clinical trials in type 1 Gaucher disease, and 58% of patients in a clinical trial in Niemann-Pick type C disease reported tremor on treatment.”
> “Gastrointestinal events, mainly diarrhoea, have been observed in more than 80% of patients, either at the outset of treatment or intermittently during treatment (see section 4.8).”
> “Cases of Crohn’s disease have been reported post-marketing in Niemann-Pick type C disease patients treated with Zavesca.”
> “Reliable contraceptive methods should be maintained while male patients are taking Zavesca and for 3 months following discontinuation.”
> “The benefit of treatment with Zavesca for neurological manifestations in patients with Niemann-Pick type C disease should be evaluated on a regular basis, e.g. every 6 months; continuation of therapy should be re-appraised after at least 1 year of treatment with Zavesca.”
> “In patients included in the clinical trial, 40%-50% had platelet counts below the lower limit of normal at baseline. Monitoring of platelet counts is recommended in these patients.”
> “Growth should be monitored in paediatric and adolescent patients during treatment with Zavesca; the benefit/risk balance should be re-assessed on an individual basis for continuation of therapy.”

Source: [European Medicines Agency Zavesca product information (2026)](https://www.ema.europa.eu/en/documents/product-information/zavesca-epar-product-information_en.pdf)

<a id="topic-2.1.2.14-26"></a>

### Miglustat: most common adverse reactions in European Union labeling

> “The most common adverse reactions reported in clinical studies with Zavesca were diarrhoea, flatulence, abdominal pain, weight loss and tremor (see section 4.4).”
> “The most common serious adverse reaction reported with Zavesca treatment in clinical studies was peripheral neuropathy (see section 4.4).”

Source: [European Medicines Agency Zavesca product information (2026)](https://www.ema.europa.eu/en/documents/product-information/zavesca-epar-product-information_en.pdf)

<a id="topic-2.1.2.14-27"></a>

### Remibetadex (intravenous hydroxypropyl-beta-cyclodextrin, Trappsol Cyclo): investigational status and proposed use

> “Potential to become treatment for the neurovisceral manifestations of NPC in adult and pediatric patients from birth (proposed indication)”
> “Only investigational NPC therapy given IV – addressing visceral disease, studied from birth, and not dependent on swallowing”
> “Two oral NPC therapies approved in the U.S. in 2024”
> “Remibetadex is an investigational drug that has not been approved by FDA or any other regulatory authority, and its pricing has not been established.”

Source: [Rafael Holdings investor presentation (2026)](https://www.sec.gov/Archives/edgar/data/1713863/000121390026117552/ea031154001ex99-1.htm)

## Related pages
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Terms and abbreviations](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations.md)
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Product information and disease description](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Clinical evidence](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Economic information and modeling report](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: References](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references.md)
